Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T72168 Target Info
Target Name Mineralocorticoid receptor (MR)
Synonyms Nuclear receptor subfamily 3 group C member 2; Mineralocorticoid receptor; MLR; MCR; Inner ear mineralocorticoid receptor; Delta
Target Type Successful Target
Gene Name NR3C2
Biochemical Class Nuclear hormone receptor
UniProt ID
MCR_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
World Intellectual Property Organization (WIPO)
Patent ID WO2014014794
Title Mineralocorticoid Receptor Antagonists.
Abstract The present invention is directed to compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, that may be useful for treating aldosteronemediated diseases. The invention furthermore relates to specific diastereomers and enantiomers of the compounds, to processes for preparing compounds of the Formula (I), to their potential use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula (I).
Applicant(s) Merck Sharp & Dohme Corp
Patent ID WO2013055608
Title Mineralocorticoid Receptor Antagonists.
Abstract The present invention is directed to compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, that are possible useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula (I), to their possible use for the treatment of the above mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula (I).
Applicant(s) Merck Sharp & Dohme Corp
Patent ID WO2013055607
Title Mineralocorticoid Receptor Antagonists.
Abstract The present invention is directed to compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, that are aldosterone receptor antagonists which might be useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula (I), to their possible use for the treatment of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula (I).
Applicant(s) Merck Sharp & Dohme Corp
Patent ID WO2013055606
Title Mineralocorticoid Receptor Antagonists.
Abstract The present invention is directed to compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, that are potentially useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula (I), to their possible use in the treatment of the above mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula (I).
Applicant(s) Merck Sharp & Dohme Corp
Patent ID WO2012139495
Title Mineralocorticoid Receptor Antagonists.
Abstract Compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, that may be useful for treating aldosterone-mediated diseases are disclosed. Processes for preparing compounds of the Formula (I), use of the compounds for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and pharmaceutical compositions which comprise compounds of the Formula (I) are disclosed.
Applicant(s) Merck Sharp & Dohme Corp
United States Patent and Trademark Office (USPTO)
Patent ID US20150284376
Title Mineralocorticoid Receptor Antagonists.
Applicant(s) Merck Sharp & Dohme Corp
Representative Drug(s) D01VJR Drug Info N.A. Click to Show More [1]
2 D02LAD Drug Info N.A. [1]
3 D08NNH Drug Info N.A. [1]
4 D0LZ4V Drug Info N.A. [1]
5 D0NC3Q Drug Info N.A. [1]
6 D0W5ZQ Drug Info N.A. [1]
Patent ID US8933113
Title Mineralocorticoid Receptor Antagonists.
Applicant(s) Merck Sharp & Dohme
Representative Drug(s) D0W5ZQ Drug Info N.A. [1]
European Patent Office (EPO)
Patent ID EP2665707
Title Mineralocorticoid Receptor Antagonists.
Applicant(s) Merck Sharp & Dohme
Representative Drug(s) D02LAD Drug Info N.A. [1]
References  Top
REF 1 Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1.Expert Opin Ther Pat. 2016 Sep 14:1-4.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.